Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenegermin - Dompe Farmaceutici

Drug Profile

Cenegermin - Dompe Farmaceutici

Alternative Names: Cenegermin-bkbj; Nerve growth factor - Anabasis/Dompe; Ophtha-NGF; Ophtha-NGF Intravitreal; Oxervate; rhNGF; Sentinel

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anabasis Pharma
  • Developer Dompe Farmaceutici; Ospedale San Raffaele
  • Class Anti-inflammatories; Antiglaucomas; Eye disorder therapies; Nerve growth factors; Neuroprotectants; Proteins
  • Mechanism of Action Nerve growth factor receptor agonists; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Keratitis
  • Phase III Dry eyes
  • Phase II Glaucoma; Retinitis pigmentosa
  • Phase I Eye disorders

Most Recent Events

  • 22 Jan 2024 Dompe Farmaceutici initiates a phase II trial for Dry eyes in Italy and USA (NCT06244316)
  • 13 Mar 2023 Phase-I clinical trials in Eye disorders in Italy (Intravitreous) before 2023 (Dompe-Farmaceutici pipeline, March 2023)
  • 19 Dec 2022 Dompé Farmaceutici completes a phase-III trial in Dry eyes in USA and Italy (Ophthalmic) (NCT05133180) (EudraCT2021-003346-21)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top